Atorvastatin reduces plasma levels of chemokine (CXCL10) in patients with Crohn's disease.
about
Current stage in inflammatory bowel disease: What is next?Current and Emerging Uses of Statins in Clinical Therapeutics: A ReviewPharmacologic inhibition of CXCL10 in combination with anti-malarial therapy eliminates mortality associated with murine model of cerebral malariaMedical therapy of stricturing Crohn's disease: what the gut can learn from other organs - a systematic review.2',3'-cAMP, 3'-AMP, 2'-AMP and adenosine inhibit TNF-α and CXCL10 production from activated primary murine microglia via A2A receptors.Association between statin use and uveitis: results from the Pacific Ocular Inflammation studyCXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications.Validation of gene expression biomarker analysis for biopsy-based clinical trials in Crohn's diseaseStatins are associated with reduced use of steroids in inflammatory bowel disease: a retrospective cohort study.Circulating markers of vascular injury and angiogenesis in antineutrophil cytoplasmic antibody-associated vasculitis.A common rejection module (CRM) for acute rejection across multiple organs identifies novel therapeutics for organ transplantation.Serum Cytokine Profiles in Children with Crohn's Disease.Function of the intestinal epithelium and its dysregulation in inflammatory bowel disease.Crohn's disease: evidence for involvement of unregulated transcytosis in disease etio-pathogenesisChemokine-dependent B cell-T cell interactions in chronic lymphocytic leukemia and multiple myeloma - targets for therapeutic intervention?Carotid intima-media thickness in patients with inflammatory bowel disease: a systematic review.Epidemiology, risk factors and management of cardiovascular diseases in IBD.Eldelumab [anti-interferon-γ-inducible protein-10 antibody] Induction Therapy for Active Crohn's Disease: a Randomised, Double-blind, Placebo-controlled Phase IIa Study.Potential Immunomodulatory Effects of Statins in Inflammatory Bowel Disease.Atorvastatin promotes the expansion of myeloid-derived suppressor cells and attenuates murine colitis.An overview of lipid abnormalities in patients with inflammatory bowel diseaseAtorvastatin therapy reduces interferon-regulated chemokine CXCL9 plasma levels in patients with systemic lupus erythematosus.Elevated serum interferon γ-inducible protein-10 in women with polycystic ovary syndrome.Response to Cote-Daigneaut et al.Analysis of the immunological biomarker profile during acute Zika virus infection reveals the overexpression of CXCL10, a chemokine linked to neuronal damage.
P2860
Q26777429-A870C584-AED5-4D33-ACB6-4423E6296537Q28076346-9F4BFA78-349D-4CAB-A6F5-0C521BFFEF88Q28486022-BBEED594-A532-4657-A662-70ABA672EC03Q34504710-C6DA219C-4A63-4283-8B30-9C56AD14AB81Q34674936-5A0A08BB-754E-44AE-8D98-D8453634DF84Q35181364-132D1618-BFF8-4BEF-A91D-30132B9ADCA4Q35469531-E7683694-7210-4EDB-8486-C3E35957C85BQ35498214-504A905D-090B-4CF2-890B-0E04728C4B21Q35541718-8E49E423-5A75-499E-9D57-4FDACBBD3F19Q35583154-F4C86F8A-E968-4943-8917-5A244810999CQ37246506-F39C8B01-3EC7-4173-AB04-8CAB6778614CQ37533500-6A45CC41-5EAF-4DC8-934E-37F2801779BDQ37774322-97597273-74B6-43A9-BE2B-EC75246F7195Q37862587-A587CC1C-39B4-453D-905D-359BA49F730FQ37983913-3E20357F-5554-425F-9EF9-130692D897F8Q38083042-EDFDA1AA-3A40-4656-890B-FCE1B112AB31Q38275040-224F5E3D-7587-4335-B6E2-B51E0807B64AQ38379118-2B232BCF-F81D-42E9-8C6E-86638F027565Q38711126-F503CF2F-31BD-4978-A0F1-13756CB35392Q39169148-4C221830-B9F3-4EDE-BCC4-42CECC39233FQ42406811-F5D90B6F-845C-4F51-80BE-2654DBCD7664Q43089915-5075A932-8EFF-4445-BE39-93CE65BA83C9Q51218774-153C0B48-02C1-4AC0-A790-5D018AC9B16BQ53644619-406CB223-2D84-4C34-B047-87D982498CE7Q54209920-D1115CED-2488-40F0-BD25-D0FF4C84941C
P2860
Atorvastatin reduces plasma levels of chemokine (CXCL10) in patients with Crohn's disease.
description
2009 nî lūn-bûn
@nan
2009 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Atorvastatin reduces plasma le ...... patients with Crohn's disease.
@ast
Atorvastatin reduces plasma le ...... patients with Crohn's disease.
@en
type
label
Atorvastatin reduces plasma le ...... patients with Crohn's disease.
@ast
Atorvastatin reduces plasma le ...... patients with Crohn's disease.
@en
prefLabel
Atorvastatin reduces plasma le ...... patients with Crohn's disease.
@ast
Atorvastatin reduces plasma le ...... patients with Crohn's disease.
@en
P2860
P1433
P1476
Atorvastatin reduces plasma le ...... patients with Crohn's disease.
@en
P2093
P2860
P356
10.1371/JOURNAL.PONE.0005263
P407
P577
2009-05-06T00:00:00Z